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A B S T R A C T
Background: Maxillary sinus cancer is a rare disease with heterogeneous biologic behavior. The pattern of neurovascular invasion is known to be an important
prognosticator in head and neck cancers, but has not been studied in maxillary malignancies.
Materials and methods: Patients undergoing surgery-based treatment with curative intent for a malignancy of the maxillary sinus at the Unit of Otorhinolaryngology –
Head and Neck Surgery of the University of Brescia between November 2000 and October 2018 were included. A description of the characteristics of the patients,
tumors, and treatments has been performed along with uni- and multi-variate analysis of prognostic factors. Tumors were classified based on the presence of
perineural (P0/P1) and lymphovascular invasion (V0/V1) in 4 categories: P0V0, P1V0, P0V1, and P1V1.
Results: One hundred-thirty-eight patients were included. Mean age at surgery was 61.0 years. Most patients (60.1%) were affected by non-salivary carcinomas, and
most tumors (73.9%) were high-grade cancers. One hundred-seven (77.5%) tumors were classified as pT4. The large majority of patients received bi- or tri-modality
treatment. Sixty-three (45.7%) cases were classified as P0V0, 32 (23.2%) as P1V0, 7 (5.1%) as P0V1, and 36 (26.1%) as P1V1. T category, nodal status, and neuro-
vascular invasion were significantly associated with prognosis. Perineural and lymphovascular invasion were associated with the topographical growth of the tumor.
Conclusions: Maxillary cancer is often diagnosed at an advanced stage and in most cases requires a multimodal approach. Perineural and lymphovascular invasion are
frequent and have a different impact on prognosis and topographical extension of the tumor.
Introduction
Maxillary sinus cancer is a relatively rare entity that poses several
challenges to head and neck (HN) physicians. The site of origin has the
peculiarity of limiting early diagnosis while facilitating silent involve-
ment of critical structures. From a prognostic perspective, this trans-
lates into late diagnosis and poor outcomes [1–3]. The currently
available literature on maxillary cancer is mostly based on single-his-
tology series including squamous cell carcinoma (SCC) and adenoid
cystic carcinoma (ACC) [4–10], with little reported on other histologies
[1]. This somehow conflicts with the well-settled knowledge that his-
tology substantially affects behavior of sinonasal tumors [11,12].
To date, surgery still represents the cornerstone in the management
of maxillary cancer, being the upfront step in most cases. The ablative
phase consists of maxillectomy, which can be tailored according to
tumor extension. During assessment of tumor margins and osteotomy
planning, endoscopy and surgical navigation, respectively, can aid the
surgeon in achieving a resection with free margins [13–15]. With the
infrequent exception of early cancers which are radically excised,
treatment also includes adjuvant radiation [16,17]. Moreover, che-
motherapy can be used in combination with radiotherapy and/or in the
induction setting to modulate the treatment schedule, facilitate orbit
preservation and/or improve oncologic results [18–21]. Particle
therapy, due to the possibility of better shaping the distribution of ra-
diation doses, has been proposed as an attractive option for advanced
maxillary cancers [22,23].
Over the last 3 decades, the evolution of the indications for endo-
scopic surgery for sinonasal malignancies has focused interest towards
nasoethmoidal tumors, which are more frequently amenable to trans-
nasal endoscopic resection. On the contrary, maxillary sinus cancers are
rarely manageable with a purely endoscopic approach and have con-
sequently raised less attention in the contemporary literature. Even if
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multimodal treatment schedules have improved survival rates [8], 5-
year overall survival (OS) of patients treated for maxillary cancer still
ranges between 30.0% and 62.0% [2,24–27], with a number of factors
affecting prognosis including local and regional extension, tumor grade,
margin involvement, perineural invasion (PNI), and lymphovascular
invasion (LVI) [2,28–30]. These data suggest that maxillary sinus
cancer still represents a field within HN oncology that deserves to be
better understood and explored.
The ways that tumors of the HN tend to invade surrounding tissues
through nerves and vessels has raised particular interest, especially in
view of the fact that cancers exhibiting PNI and/or LVI are associated
with poor outcomes (with special reference to ACC) [18,31–37].
Moreover, the pattern of neural and vascular invasion is known to be
associated with histology, as different sinonasal cancers display PNI and
LVI with heterogeneous frequency [38].
The present study analyzed oncologic data on a series of patients
with cancers of the maxillary sinus treated over an 18-year period,
under the hypothesis that PNI and LVI significantly affected the pattern
of local extension along with the probability and pattern of recurrence.
Materials and methods
The institutional database of patients receiving surgery for sinonasal
cancer at the Unit of Otorhinolaryngology – HN Surgery of the
University of Brescia was retrospectively analyzed. Patients who un-
derwent surgery-based treatment with curative intent for maxillary
sinus malignancies between November 2000 and October 2018 were
included in the study. Patients undergoing palliative surgery, affected
by benign neoplasms, or tumors originating from nasoethmoidal com-
plex, oral cavity, hard palate, or orbit were excluded. Indication to
maxillectomy was given in keeping with general principles of oncologic
HN surgery [3]. Tumors with critical posterior and/or superior exten-
sion towards the skull base were managed as described by Deganello
et al. [14]. The present study was approved by the local ethics board
(protocol number: NP3616).
Demographics, oncologic, and pathologic information
Information on demographics (gender, age at surgery), tumor
characteristics (histology, grade, anatomical extent), previous treat-
ment(s), surgery, and adjuvant therapy were retrieved. Histological
nomenclature and classification were adapted to the 4th edition of the
“WHO classification of HN tumors” [39]. Margin status, presence of PNI
and/or LVI, and local, regional, and distant extension of the tumor were
re-classified according to the 8th edition of the “TNM classification of
malignant tumors” [40]. Margins were primarily evaluated on the main
surgical specimen. When an additional specimen was uninvolved and
orientable as additional resection with respect to a positive margin on
the main surgical specimen, that margin was considered as clear.
Otherwise, if a positive margin was detected on the main specimen with
additional specimens being infiltrated and/or non-orientable, the
margin status was precautionary defined as involved. PNI was defined
as the presence of tumor cells within the perineural space [41]. Inva-
sion of the epineurium with no extension within the perineural space
was not sufficient to be classified as PNI. Intraneural invasion was di-
agnosed when tumor cells were intermingled with neural fibers. LVI
was defined if tumors cells were found within vascular wall and/or
lumen.
Poorly differentiated SCC, high-grade mesenchymal malignancies,
ACC exhibiting a solid component [42], and other tumors indicated as
high-grade according to the 4th edition of the “WHO classification of
HN tumors” criteria were grouped under the term “high-grade tumors”
[39]. Well- and moderately-differentiated SCC, low-grade mesenchymal
malignancies, and ACC without a solid component were grouped under
the term “low-grade tumors”.
Areas and structures surrounding the maxillary sinus were divided
in 33 anatomical subunits (Supplementary Table 1). Each anatomical
subunit was defined as invaded or non-invaded by the tumor based on
systematic analysis of the final histologic description, surgical report,
and preoperative imaging, following this hierarchical order. The fre-
quency of invasion of each subunit was assessed.
Each tumor was attributed to one of the following 4 groups: P0V0 –
tumors with neither PNI nor LVI; P1V0 – tumors with PNI alone; P0V1 –
tumors with LVI alone; P1V1 – tumors with both PNI and LVI. This
categorization was defined as “pattern of neurovascular invasion”.
Distribution of histologies within the 4 patterns of neurovascular in-
vasion was assessed.
Statistical analysis
Descriptive statistics were used for each variable assessed. The as-
sociation of pattern of neurovascular invasion with histology, grade,
and margin status were analyzed with Chi-square test or Fisher’s exact
test, as appropriate. The associations between pattern of neurovascular
invasion and involvement of anatomical structures and areas sur-
rounding the maxillary sinus were studied with the same method. The
isolated effect of PNI and LVI on involvement of anatomical structures
was tested through a sub-analysis of P1V0 versus P0V0 tumors and P0V1
versus P0V0 tumors, respectively. Rates of nodal involvement in low
versus high grade tumors and within different histological groups were
compared with Chi-square test or Fisher’s exact test, as appropriate.
Follow-up duration and patient status at last evaluation were ana-
lyzed. Overall (OS), disease-specific (DSS), recurrence-free (RFS), local
recurrence-free (LRFS), regional recurrence-free (RRFS), and distant
recurrence-free (DRFS) survivals were evaluated with the Kaplan-Meier
method. Age at surgery, gender, presentation (i.e. primary vs recur-
rence), pT category (i.e. pT4 vs pT1-T3), presence of nodal metastases
(i.e. pN+ vs N0), histological category (i.e. non-salivary carcinomas vs
salivary carcinomas vs mesenchymal tumors vs neuroectodermal tu-
mors), grading (i.e. high-grade vs low-grade), PNI, LVI, pattern of
neurovascular invasion (i.e. P0V0 vs P1V0 vs P0V1 vs P1V1), margin
status (involved margins vs uninvolved margins, and involved margins
vs margins< 5 mm vs> 5 mm), and treatment schedule (tested in 3
ways as follows: comparing the 8 clusters showed in Fig. 1, considering
patients receiving vs those not receiving induction chemotherapy,
comparing patients who received a radical resection vs those with in-
volved margins receiving adjuvant (chemo)radiation vs those with in-
volved margins not receiving adjuvant (chemo)radiation) were tested
as prognosticators with univariate survival analysis based on the log
rank Mantel-Cox test. A multivariate Cox proportional hazard model
test was run to identify independent prognosticators among factors with
significance at univariate analysis. Level of significance was set at 0.05
for all statistical tests. P-values within the interval 0.05–0.10 were
defined as close-to-significant.
Results
Demographics, oncologic, and pathologic information
One hundred-thirty-eight patients were included in the study. Mean
age at surgery was 61.0 years and male-to-female ratio was 1:1. Forty-
eight (34.8%) patients presented with a recurrent tumor. Eighty-three
(60.1%) patients were affected by non-salivary carcinomas, mainly
represented by SCC. Less frequent histologies were salivary gland car-
cinomas (19.6%), mesenchymal tumors (13.8%), and neuroectodermal
tumors (6.5%) (Table 1). Most tumors (102; 73.9%) belonged to the
high-grade group.
The majority of patients were diagnosed with a high-stage (III or IV)
tumor (127 patients; 92.0%). One hundred-seven (77.5%) tumors were
classified as pT4, 58 of which (42.0%) were pT4b. Resection included
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the orbit in 42 (30.4%) patients and a large portion of the skull base in
31 (22.5%; anterior skull base in 10, middle skull base in 16, and both
in 5 patients). Nodal invasion was uncommon, with 121 (87.5%) cases
being classified as N0 (Table 2). The rate of nodal metastasis
progressively increased from neuroectodermal tumors (0.0%), to me-
senchymal cancers (5.3%), non-salivary carcinomas (12.0%), and sali-
vary malignancies (22.2%), without reaching statistical significance
(p = 0.288). Low- and high-grade maxillary malignancies had similar
rate of nodal metastases (11.1% and 12.7%, respectively; p = 0.798).
According to the final histologic examination, 71 (51.8%) patients
had microscopically involved margins, and 16 (11.6%) patients had
negative margins closer than 5 mm to the tumor. In 12/71 (16.9%)
patients with positive margins, PNI was partially or totally responsible
for margin involvement. PNI and LVI were found in 68 (49.3%) and 43
(31.2%) tumors, respectively. In 20/68 (29.4%) patients, PNI was
identified in a tissue labelled as branch/part of a named nerve (tri-
geminal, vidian, oculomotor-trochlear-abducens); in the remaining
cases, PNI was detected only in small nervous branches. Epineural in-
vasion with no PNI was observed in 28 (20.3%) patients. Intraneural
invasion was found in 23 (16.7%) tumors, all of which displayed also
PNI. Thirty-nine (28.3%) cancers showed tumor cells in both vascular
wall and lumen, whereas only 4 (2.9%) patients had a vascular wall
invaded with no intraluminal cells. According to the pattern of
Fig. 1. Flow-chart summarizing the modalities included in the treatment schedule.
Table 1
Histology distribution – ONB, Olfactory neuroblastoma; PNET, Primitive neu-
roectodermal tumor; NOS, Not otherwise specified. HClassified as high-grade
tumor, Lclassified as low-grade tumor.
Variable Distribution
Histology • Carcinomas: 83/138 (60.1%)
o Squamous cell carcinoma: 68/83 (81.9%)
▪ Keratinizing: 43/68 (63.2%)18L, 25H
▪ Non-keratinizing: 7/68 (10.3%)H
▪ Ex inverted papilloma: 7/68 (10.3%)4L, 3H
▪ Spindle cell: 4/68 (5.9%)H
▪ Adenosquamous: 3/68 (4.4%)H
▪ Basaloid: 2/68 (2.9%)H
▪ Adenoid: 1/68 (1.5%)L
▪ Papillary: 1/68 (1.5%)L
o Sinonasal neuroendocrine carcinoma: 3/83 (3.6%)H
o Carcinoma NOS: 3/83 (3.6%)H
o Intestinal-type adenocarcinoma: 2/83 (2.4%)H
o Non-intestinal-type adenocarcinoma: 2/83 (2.4%)H
o Basal cell carcinoma: 2/83 (2.4%)L
o INI-1 deficient carcinoma: 1/83 (1.2%)H
o Sinonasal undifferentiated carcinoma: 1/83 (1.2%)H• Minor salivary gland carcinomas: 27/138 (19.6%)
o Adenoid cystic carcinoma: 21/27 (77.8%)
▪ Solid: 12/21 (57.1%)H
▪ Cribriform: 7/21 (33.3%)1L, 6H
▪ Tubular: 1/21 (4.8%)L
o Salivary duct carcinoma: 2/27 (7.4%)H
o Adenocarcinoma NOS: 1/27 (3.7%)H
o Polymorphous adenocarcinoma of the salivary glands: 1/27
(3.7%)L
o Mucoepidermoid carcinoma: 1/27 (3.7%)L
o Oncocytic carcinoma 1/27 (3.7%)L
o Myoepithelial carcinoma: 1/27 (3.7%)H• Mesenchymal tumors: 19/138 (13.8%)
o Myxofibrosarcoma: 4/19 (21.0%)1L, 3H
o Undifferentiated pleomorphic sarcoma: 4/19 (21.0%)H
o Chondroblastic osteosarcoma: 3/19 (15.8%)H
o Rhabdomyosarcoma: 2/19 (10.5%)H
o Histiocytic sarcoma: 1/19 (5.3%)H
o Fibrosarcoma: 1/19 (5.3%)L
o Leiomyosarcoma: 1/19 (5.3%)H
o Myofibroblastic sarcoma: 1/19 (5.3%)L
o Myofibroblastic inflammatory tumor: 1/19 (5.3%)L
o Solitary fibrous tumor 1/19 (5.3%)L• Neuroectodermal tumors: 9/138 (6.5%)
o Mucosal melanoma: 7/9 (77.8%)H
o ONB: 1/9 (11.1%)H
o PNET: 1/9 (11.1%)
Table 2
Tumor characteristics.
Variable Distribution
pT classification • T1: 1/138 (0.7%)• T2: 10/138 (7.2%)• T3: 20/138 (14.4%)• T4: 107/138 (77.5%)
o T4a: 49/107 (45.8%)
o T4b: 58/107 (54.2%)
N classification • N0: 121/138 (87.7%)• N1: 5/138 (3.6%)• N2a: 2/138 (1.4%)• N2b: 5/138 (3.6%)• N3b: 5/138 (3.6%)
Nodal levels involved • Level I: 6/17 (35.3%)• Level II: 11/17 (64.7%)• Level III: 8/17 (47.1%)• Level IV: 2/17 (11.8%)• Level V: 3/17 (17.6%)• Level VI: 2/17 (11.8%)
UICC stage • Stage I: 1/138 (0.7%)• Stage II: 10/138 (7.2%)• Stage III: 18/138 (13.0%)• Stage IVA: 50/138 (36.2%)• Stage IVB: 59/138 (42.5%)
Perineural invasion Present: 68/138 (49.3%)
Vascular invasion Present: 43/138 (31.2%)
Pattern of neurovascular invasion • P0V0: 63/138 (45.7%)• P1V0: 32/135 (23.2%)• P0V1: 7/138 (5.1%)• P1V1: 36/138 (26.1%)
M. Ferrari, et al. Oral Oncology 106 (2020) 104672
3
neurovascular invasion: 63 (45.7%) cases were classified as P0V0, 32
(23.2%) as P1V0, 7 (5.1%) as P0V1, and 36 (26.1%) as P1V1 (Table 2).
The treatment schedules included neoadjuvant chemotherapy in 31
(22.5%) patients, 22 of which (15.9%) received surgery and adjuvant
radiation (combined with chemotherapy in 2 [1.4%] patients), 7 (5.1%)
surgery alone, and 2 (1.4%) surgery followed by adjuvant che-
motherapy. Sixty-two patients (44.9%) were treated with upfront sur-
gery followed by adjuvant radiation therapy (combined with che-
motherapy in 10 [7.2%] patients), 40 (39.0%) received surgery alone,
and 5 (3.6%) surgery with adjuvant chemotherapy (Fig. 1).
Pattern of neurovascular invasion versus histology, grade, margin status, and
topographic extent
Histological category was significantly associated with the pattern
of neurovascular invasion, with P1V0 and P1V1 tumors being more re-
presented in non-salivary carcinomas and salivary tumors (p = 0.0002)
(Table 3). Similarly, grade was associated with the pattern of neuro-
vascular invasion, as the high-grade group showed a higher rate of P1V0
and P1V1 cancers (p = 0.024) (Table 3). P0V1 and P1V1 cancers had a
higher rate of involved margins (85.7% and 72.2%, respectively) as
compared to P0V0 and P1V0 tumors (41.3% and 40.6%, respectively;
p = 0.003).
The rate of involvement of anatomical structures listed in
Supplementary Table 1 was significantly associated with the pattern of
neurovascular invasion of the tumor, especially for superior and pos-
terior structures (Table 4, Supplementary Table 2, Supplementary
Figs. 1–4). At sub-analysis, PNI had an isolated effect on involvement of
superior, posterior, and medial structures, whereas LVI was associated
with a higher rate of involvement of inferior structures, yet not reaching
statistical significance (Supplementary Table 3). Nodal metastases were
more frequently found in P0V1 (28.6%) and P1V1 (22.2%) tumors
(Table 4, Supplementary Table 2). Consistently, the probability of
having nodal metastasis was significantly associated with the presence
of LVI (relative risk: 3.16, p = 0.009) while it was independent of PNI
(relative risk: 1.89, p = 0.174).
Oncologic outcomes
Mean duration of follow-up was 38.9 months. Three- and 5-year
survival estimates were 60.7% and 52.4% for OS, 62.6% and 57.2% for
DSS, 47.5% and 41.0% for RFS, 63.5% and 56.8% for LRFS, 81.8% and
81.8% for RRFS, and 76.4% and 69.7% for DRFS. At univariate analysis,
high pT category (pT4), nodal metastasis, PNI, LVI, and pattern of
neurovascular spread had a significant negative impact on the majority
of outcomes (Table 5). Age at surgery, gender, presentation, histolo-
gical category, grading, margin status, and treatment schedule were not
significantly associated with any outcome. The pattern of neurovascular
spread was excluded from the multivariate analysis as it would have
implied a redundancy of information with regards to PNI and LVI
considered separately. Nodal metastasis and PNI were independent
prognostic factors for OS, DSS, and RFS (Table 5, Fig. 2). The pattern of
recurrence was poorly predictable by the multivariate model, as no
factor was significantly independent when analyzing LRFS, RRFS, and
DRFS (Table 5).
Discussion
The present study analyzed 138 patients treated for maxillary sinus
cancer over an 18-year period in a single referral center. An important
finding is that most maxillary cancers were diagnosed at a locally very
advanced stage, with 42.0% of tumors classified as pT4b. This is likely
caused by the silent and non-specific symptoms that these tumors give
rise to during initial growth. Another factor related to advanced-stage
presentation is that more than half of cancers grow along nerves, ves-
sels, or both, which substantially guide the local extension of tumor.
Specifically, P1V0 and P1V1 tumors showed a propensity to invade su-
perior, medial, and posterior structures, while the presence of LVI (i.e.
P0V1 and P1V1 tumors) was associated with a higher rate of infiltration
of inferior structures and nodal metastasis. This translated into a sig-
nificant association between pattern of neurovascular invasion and
prognosis, with special reference to OS, DSS, RFS, LRFS, and DRFS. PNI
and nodal involvement were also confirmed as independent negative
prognosticators at multivariate analysis, as observed in other studies
[30,33,43–45]. Notably, nodal involvement was most frequently found
in salivary malignancies independently of the grade.
The descriptive breakdown of the present series reflects several
historical and emerging issues related to maxillary cancer. Beside the
well-known tendency for advanced stage presentation (Table 2), the
histological diversity of tumors arising from the maxilla was well re-
presented in this series, with 39.9% of cancers classified as non-SCC
malignancies (Table 1). Minor salivary gland carcinomas, mesenchymal
malignancies, and neuroectodermal tumors were mainly constituted of
ACC, soft tissue sarcomas, and mucosal melanoma, respectively. The
heterogeneity of the multidisciplinary treatment schedule, which re-
sulted in 8 clusters of modalities (Fig. 1), reflects the effort of tailoring
therapy according to the biological behavior of the tumor. This concept
is soundly settling into the management philosophy of sinonasal cancer.
Most importantly, 22.5% of patients underwent induction che-
motherapy, which is progressively and proficiently used in manage-
ment of cancers of the sinonasal tract [18,46,47], with special reference
to the potential of reliably guiding definitive treatment [20] and in-
creasing the probability of functional eye preservation [21]. In the
present retrospective study, induction chemotherapy did not provide a
survival benefit at univariate analysis. However, this result is deeply
biased by the inclusion of tumors with diverse histology and pre-
sentation. Of note, a number of patients included in this analysis were
recruited in SINTART1, which is a phase 2 trial prospectively assessing
the potential benefit of multidisciplinary management including in-
duction chemotherapy with histology-driven regimen and state-of-the-
art radiation therapy in patients affected by operable sinonasal cancers
(Clinicaltrials.gov identifier: NCT02099175). The trial will provide
more information on the role of induction chemotherapy in selected
sinonasal malignancies (poorly differentiated SCC, sinonasal un-
differentiated carcinoma, sinonasal neuroendocrine carcinoma, and
adenocarcinoma), and the recruitment phase has been recently closed.
In the present series, a substantial portion (39.0%) of patients were
treated with surgery alone. This cluster includes both early (T1-T2, N0
tumors) and recurrent cancers that were previously irradiated, the
latter hardly being candidates for adjuvant re-irradiation. Interestingly,
recurrent cancers were not associated with unfavorable prognosis, thus
Table 3
Association of grade and histology with the pattern of neurovascular invasion.
Feature P0V0 P1V0 P0V1 P1V1 p-value
Grade Low-grade (n = 36) 23 (63.9%) 8 (22.2%) 2 (5.6%) 3 (8.3%) 0.014
High-grade (n = 102) 40 (39.2%) 24 (23.5%) 5 (4.9%) 33 (32.4%)
Histology Carcinomas (n = 83) 41 (49.4%) 16 (19.3%) 5 (6.0%) 21 (25.3%) <0.0001
Mesenchymal tumors (n = 19) 14 (73.7%) 2 (10.5%) 1 (5.3%) 2 (10.5%)
Neuroectodermal tumors (n = 9) 6 (66.7%) 2 (22.2%) 1 (11.1%) 0 (0.0%)
Salivary tumors (n = 27) 2 (7.4%) 12 (44.4%) 0 (0.0%) 13 (48.1%)
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suggesting that tumor presentation is likely eclipsed by other prognostic
factors, when salvage surgery is feasible.
Almost half of resections had involved margins, which in turn did
not imply a significant worsening of prognosis. The absence of a mea-
surable impact on outcomes, which contrasts with other published
series [48,49], might be caused by histological heterogeneity and other
confounders such as the systematic use of defect-driven frozen-sections
and, when indicated, additional specimens. In fact, when uninvolved
additional specimens were not clearly orientable with respect to a po-
sitive margin on the main specimen, the margin status was considered
as involved on a precautional basis, thus possibly leading to over-
estimation of margin infiltration. Bristol et al. found that margin status
was not significantly associated with prognosis at univariate analysis,
but was independently associated with survival when inserted in a
multivariate model, thus confirming that clear margins should be pur-
sued whenever possible [17]. In the present study, the number of events
did not allow the inclusion in multivariate analysis of variables not
showing significance at univariate analysis [50]. In agreement with
another study [17], a margin<5 mm did not translate into poorer
survival. This finding suggests that the general definition of “close
margins” used for oral cancer may not apply to sinonasal malignancies.
Of note, 41 of 71 (57.7%) patients with positive margins underwent
adjuvant radiotherapy with state-of-the-art methodology including in-
tensity-modulated radiation therapy, high dose (i.e. 66 Gy) in high-risk
volumes, and concomitant chemotherapy, whenever indicated ac-
cording to histologic features and the patient’s conditions. Among these
patients, 9 of 20 (45.0%) who had previously received radiation un-
derwent re-irradiation. This multidisciplinary approach might have
mitigated the negative prognostic effect of margin involvement. The
non-negligible rate of patients not receiving adjuvant treatment despite
margin involvement (30/71, 42.3%) was mostly related to the patient’s
refusal to undergo radiotherapy or to ineligibility to radiation within
the 2-month postoperative window due to comorbidities and/or com-
plications. The fact that this subgroup was not associated with worse
survival should be interpreted cautiously, as a number of factors might
have biased this result (e.g. histological heterogeneity with different
event-free latency, overestimation of positive margins). Overall, it can
be concluded that control of surgical margins in maxillary cancer is an
unmet challenge and should attract the attention of researchers in HN
oncology.
In the present series, 5-year OS and RFS were 52.4% and 41.0%,
respectively, with the majority of patients experiencing local and dis-
tant recurrences. On one hand, these results imply a large room for
improvement, while on the other hand, when contextualizing these
data within a timeline of maxillary cancer oncologic outcomes, an en-
couraging trend can be seen. As already shown by Dulguerov et al. [51],
5-year OS of patients treated for maxillary cancer progressively in-
creased from 20–35% in 60–70ies [52–55], to 30–47% in the 80–90ies
[24–26], up to 58–71% in the last 2 decades [9,56]. However, a
prognostic model based on the Surveillance Epidemiology and End
Results (SEER) database reports a 5-year OS as low as 39.7% in 668
patients treated between 2004 and 2013 [27]. Moreover, it is worth
highlighting that the concept of “resectability” is also evolving, as very
advanced sinonasal cancers (i.e. T4b tumors), which represented a
considerable portion of the present series (42.0%), have been con-
sidered suitable for upfront surgery only in recent times [57].
Although PNI and LVI have been already considered distinctly in
sinonasal cancers [37,38], to the best of our knowledge this is the first
study analyzing the two modalities of growth simultaneously by de-
fining the pattern of neurovascular invasion, which was associated with
all oncologic outcomes except RRFS.
Histology and grade were significantly associated with the pattern
Table 4
Association between local extension, expressed as frequency of structures involvement, and pattern of neurovascular invasion.
Topography Structure P0V0 P0V1 P1V0 P1V1 p-value
Superior structures Overall (superior) 50.8% 42.9% 81.3% 88.9% <0.0001
Infraorbital nerve 31.7% 42.9% 56.3% 69.4% 0.002
Inferior orbital fissure 15.9% 14.3% 43.8% 61.1% <0.0001
Orbital floor/periorbit 44.4% 28.6% 75.0% 66.7% 0.007
Intraorbital structures 20.6% 28.6% 43.8% 41.7% 0.049
Superior orbital fissure 1.6% 0.0% 21.9% 30.6% <0.0001
Frontal sinus 6.3% 0.0% 12.5% 11.1% 0.653
Inferior structures Overall (inferior) 65.1% 85.7% 68.8% 91.7% 0.015
Hard palate 52.4% 71.4% 50.0% 86.1% 0.002
Alveolar process 58.7% 71.4% 59.4% 75.0% 0.372
Soft palate 6.3% 0.0% 25.0% 13.9% 0.058
Buccinator muscle 19.0% 14.3% 18.8% 22.2% 0.970
Medial structures Overall (medial) 54.0% 42.9% 78.1% 83.3% 0.004
Ethmoid 34.9% 28.6% 56.3% 69.4% 0.004
Nasolacrimal duct 36.5% 14.3% 53.1% 52.8% 0.114
Nasal septum 23.8% 42.9% 46.9% 44.4% 0.060
Lateral structures Overall (lateral) 69.8% 57.1% 75.0% 77.8% 0.622
Infratemporal fat 38.1% 28.6% 50.0% 63.9% 0.067
Temporal/masseteric muscle 19.0% 28.6% 28.1% 36.1% 0.287
Zygomatic bone 50.8% 57.1% 65.6% 52.8% 0.583
Anterior structures Premaxillary tissues 47.6% 57.1% 68.8% 58.3% 0.261
Posterior structures Overall (posterior) 47.6% 42.9% 75.0% 97.2% <0.0001
Pterygopalatine fossa 30.2% 28.6% 62.5% 91.7% <0.0001
Pterygoid plates 25.4% 14.3% 43.8% 86.1% <0.0001
Pterygoid muscles 23.8% 28.6% 46.9% 66.7% 0.0002
Branches of V3 9.5% 0.0% 28.1% 36.1% 0.004
Foramen rotondum 3.2% 14.3% 28.1% 58.3% <0.0001
Foramen ovale 6.3% 0.0% 18.8% 25.0% 0.037
Vidian nerve/canal 7.9% 14.3% 43.8% 52.8% <0.0001
Meckel’s cave 0.0% 0.0% 9.4% 13.9% 0.012
Cavernous sinus 0.0% 0.0% 18.8% 19.4% 0.0004
Nasopharynx 14.3% 0.0% 40.6% 55.6% <0.0001
Sphenoid 15.9% 0.0% 37.5% 58.3% <0.0001
Lateral middle skull base 9.5% 0.0% 31.3% 36.1% 0.003
Nodal metastases 6.4% 28.6% 9.4% 22.2% 0.051
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of neurovascular invasion. This finding suggests that PNI and LVI re-
present a gain of function that is acquired more frequently by high-
grade tumors, with special reference to salivary and non-salivary car-
cinomas, while mesenchymal and neuroectodermal cancers rarely dis-
play these features [38]. Moreover, analysis of the pattern of neuro-
vascular invasion allowed the observation that LVI is rarely found
alone, with only 7 of 43 (16.3%) cancers with LVI classified as P0V1
(Table 2). The fact that most tumors with LVI also displayed PNI could
be related to some overlap between the molecular mechanisms behind
these histologic modalities of growth. In fact, phenomena such as
macrophage recruitment and overexpression of metalloproteinases are
observed in both PNI and LVI, while other biological mechanisms are
specific for only one type of invasion (e.g. overexpression of CCR2 and
CXCR5 for PNI and CCR7 for LVI) [58–60].
The most original finding of the present study is that the pattern of
neurovascular invasion significantly affected the invasion of anatomical
structures neighboring the maxillary sinus with an eccentric topo-
graphy. Apart from ACC (21 patients), which is well known to display
PNI and possibly LVI, it is of note that most tumors with P1V0, P0V1, and
P1V1 pattern were non-salivary carcinomas (16, 5, and 21 patients,
respectively). P1V0 and P1V1 malignancies tended to invade superior,
medial, and posterior structures more frequently compared to other
tumors (Supplementary Figs. 2 and 4), while P0V1 and P1V1 tumors
showed a propensity towards invasion of the hard palate and nodal
metastasis (Supplementary Figs. 3 and 4). This observation is in line
with other studies that suggested that there might be correlation be-
tween neurovascular invasion, tumor origin, and local extension: Singh
et al. showed that HN ACC has a propensity to grow towards the orbit
and skull base by following the trigeminal-facial network [61]; Martins-
Andrade et al. reported that the risk of nodal metastasis in HN ACCs was
more than doubled when LVI was detected [37]; Liu et al. found that
PNI and LVI were heterogeneously frequent in different oral SCCs de-
pending upon the subsite of origin [35]. The concept of correlation
between pattern of neurovascular invasion and propensity of the tumor
to invade specific anatomical area could be of value to physicians who
need to delineate a boundary of treatment (e.g. target contouring for
radiation).
The present study has some limitations that cannot be neglected:
first, it is based on a retrospective analysis of patients over an 18-year
period; second, the total number of events (48 patients dead of any
Fig. 2. Kaplan-Meier plots showing the prognostic impact of nodal status and pattern of neurovascular invasion on overall, local recurrence-free, and distant
recurrence-free survival. Compare with Table 5 for p-values.
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cause) limited multivariate analysis to include 4 factors; third, the
variety of histologies forced us to a simplistic classification of tumors in
4 categories.
Conclusion
The present study suggests that maxillary cancer represents an open
issue in HN oncology. Pattern of neurovascular invasion affects the
local spread of tumor and physicians delivering locoregional treatment
should be aware of this finding. Achieving clear margins is a challenge.
Since PNI decreases survival independently of other variables, it ap-
pears to be a logical target for biological and pharmaceutical research
aimed at improving efficacy of treatment in patients with sinonasal
cancer. Nodal metastasis is favored by LVI and has a negative impact on
prognosis, findings that are even more relevant compared to other HN
cancers.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.oraloncology.2020.104672.
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